BRPI0515893A - peptìdeos da proteìna humana de estresse térmico, composição farmacêutica e método de tratamento da artrite reumatóide - Google Patents

peptìdeos da proteìna humana de estresse térmico, composição farmacêutica e método de tratamento da artrite reumatóide

Info

Publication number
BRPI0515893A
BRPI0515893A BRPI0515893-1A BRPI0515893A BRPI0515893A BR PI0515893 A BRPI0515893 A BR PI0515893A BR PI0515893 A BRPI0515893 A BR PI0515893A BR PI0515893 A BRPI0515893 A BR PI0515893A
Authority
BR
Brazil
Prior art keywords
rheumatoid arthritis
peptides
stress protein
pharmaceutical composition
heat stress
Prior art date
Application number
BRPI0515893-1A
Other languages
English (en)
Inventor
Horta Maria Del Carmen Dominguez
Gabriel Ramon Padron Palomares
Nelia Lopez Marim
Norailys Lorenzo Perez
Ariana Barbera Betancourt
Garcia Ariadna Hernandez
Cordova Vivian Morera
Diaz Carelia Cosme
Garcia Nelson J Merino
Ariel Vazquez Bonachea
Jose Suarez Alba
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to BR122018077204A priority Critical patent/BR122018077204B8/pt
Publication of BRPI0515893A publication Critical patent/BRPI0515893A/pt
Publication of BRPI0515893A8 publication Critical patent/BRPI0515893A8/pt
Publication of BRPI0515893B1 publication Critical patent/BRPI0515893B1/pt
Publication of BRPI0515893B8 publication Critical patent/BRPI0515893B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"PEPTìDEOS DA PROTEìNA HUMANA DE ESTRESSE TéRMICO, COMPOSIçãO FARMACêUTICA E MéTODO DE TRATAMENTO DA ARTRITE REUMATóIDE". Peptídeos da proteína humana de estresse térmico de 60 kDa que constituem epítopos para células T, assim como peptídeos derivados deles, os quais estão modificados nos sítios de contato com a molécula MHC, úteis para induzir mecanismos de tolerância periférica, em particular mecanismos indutores de anergia ou mediados por clones de células T regulatórias em pacientes com artrite reumatóide. A invenção também se refere a composições farmacêuticas que compreendem tais peptídeos para tratamento da artrite reumatóide.
BRPI0515893A 2004-09-24 2005-09-22 peptídeos da proteína humana de estresse térmico, composição farmacêutica, e, uso do peptídeo e da composição farmacêutica. BRPI0515893B8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122018077204A BR122018077204B8 (pt) 2004-09-24 2005-09-22 peptídeos da proteína humana de estresse térmico, composição farmacêutica, e, uso do peptídeo e da composição farmacêutica

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU20040207A CU23504A1 (es) 2004-09-24 2004-09-24 Péptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas
CU2004-0207 2004-09-24
PCT/CU2005/000008 WO2006032216A2 (es) 2004-09-24 2005-09-22 Peptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas

Publications (4)

Publication Number Publication Date
BRPI0515893A true BRPI0515893A (pt) 2008-08-12
BRPI0515893A8 BRPI0515893A8 (pt) 2019-01-02
BRPI0515893B1 BRPI0515893B1 (pt) 2020-09-15
BRPI0515893B8 BRPI0515893B8 (pt) 2021-05-25

Family

ID=40273413

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122018077204A BR122018077204B8 (pt) 2004-09-24 2005-09-22 peptídeos da proteína humana de estresse térmico, composição farmacêutica, e, uso do peptídeo e da composição farmacêutica
BRPI0515893A BRPI0515893B8 (pt) 2004-09-24 2005-09-22 peptídeos da proteína humana de estresse térmico, composição farmacêutica, e, uso do peptídeo e da composição farmacêutica.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122018077204A BR122018077204B8 (pt) 2004-09-24 2005-09-22 peptídeos da proteína humana de estresse térmico, composição farmacêutica, e, uso do peptídeo e da composição farmacêutica

Country Status (17)

Country Link
US (2) US8383771B2 (pt)
EP (2) EP2371847B1 (pt)
JP (1) JP4755649B2 (pt)
KR (2) KR101035283B1 (pt)
CN (2) CN101935345B (pt)
AR (2) AR051928A1 (pt)
AT (1) ATE546462T1 (pt)
AU (2) AU2005287757B2 (pt)
BR (2) BR122018077204B8 (pt)
CA (2) CA2581110C (pt)
CU (1) CU23504A1 (pt)
DK (2) DK2371847T3 (pt)
ES (2) ES2445707T3 (pt)
MX (1) MX2007003624A (pt)
RU (1) RU2361877C2 (pt)
WO (1) WO2006032216A2 (pt)
ZA (1) ZA200702938B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2450368A1 (en) 2007-01-30 2012-05-09 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
CU23701A1 (es) * 2008-12-29 2011-09-21 Ct Ingenieria Genetica Biotech Método de tratamiento de enfermedades inflamatorias intestinales y diabetes tipo i
JP5781514B2 (ja) * 2009-09-06 2015-09-24 プロトエービー リミテッド Ｈｓｐ６５由来のペプチド６に特異的なヒト化抗体、その方法及び使用
US20110195905A1 (en) * 2009-10-28 2011-08-11 Argentis Pharmaceuticals, Llc Apls for treating arthritis
CU24508B1 (es) * 2017-12-29 2021-04-07 Centro De Ingenieria Genetica Y Biotecnologia Biocubafarma Composición farmacéutica que comprende péptido tipo apl
CU20200026A7 (es) * 2020-04-13 2021-11-04 Ct Ingenieria Genetica Biotecnologia Péptido para el tratamiento del síndrome de la tormenta de citocinas
CN111870697B (zh) * 2020-09-18 2022-09-09 山东鲁抗医药股份有限公司 糖类物质在提高apl型衍生肽稳定性中的应用和冻干组合物
KR102333645B1 (ko) 2021-07-27 2021-12-02 (주)문화전기 각도조절이 용이한 엘이디조명시스템
CN115671253B (zh) * 2021-07-30 2024-02-27 河北菲尼斯生物技术有限公司 Se-dr亲和肽在制备治疗风湿疾病的药物中的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8701163A (nl) 1986-09-09 1988-04-05 Nederlanden Staat Gebruik van een peptide voor de bereiding van preparaten voor het verlichten, het behandelen en de diagnose van autoimmuunziekten, in het bijzonder arthritische toestanden, verbindingen die met dit peptide verwant zijn, alsmede farmaceutische en diagnostische preparaten en testkits.
NL8703107A (nl) 1987-12-22 1989-07-17 Nederlanden Staat Polypeptiden en derivaten daarvan, alsmede de toepassing daarvan in farmaceutische en diagnostische preparaten.
US5773570A (en) 1994-05-20 1998-06-30 The Regents Of The University Of California Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis
GB9419553D0 (en) 1994-09-27 1994-11-16 Univ Bristol Polypeptides and their use in the treatment of auto-immune disease
US6180103B1 (en) 1994-12-21 2001-01-30 Yeda Research And Development Co., Ltd. Peptide p277 analogs, and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes
GB9519737D0 (en) * 1995-09-27 1995-11-29 Peptide Therapeutics Ltd Polypeptides and their use in treatment and prophylaxis of auto-immune
IL120561A0 (en) * 1996-04-24 1997-07-13 Akzo Nobel Nv Peptides suitable for use in immunosuppressive therapy
US5993803A (en) 1996-08-30 1999-11-30 Yeda Research And Development Co., Ltd. Method of reducing the severity of host vs graft reaction by down-regulating hsp60 autoimmunity
GB9911772D0 (en) 1999-05-21 1999-07-21 Semmelweis University Of Medic Diagnosis and treatment of atherosclerosis
US20020169302A1 (en) * 1999-08-23 2002-11-14 Genesis Research And Development Corp. Ltd. Compositions isolated from bovine mammary gland and methods for their use
JP2004501061A (ja) * 1999-12-15 2004-01-15 ペプトル・リミテツド 熱ショックタンパク質６０のフラグメントおよびアンタゴニスト
WO2002057795A2 (en) 2001-01-19 2002-07-25 Cambridge Scientific, Inc. Methods of diagnosis and treatment of osteoporosis

Also Published As

Publication number Publication date
DK1803732T3 (da) 2012-05-29
AU2010219312A1 (en) 2010-09-23
BR122018077204B1 (pt) 2020-01-28
EP2371847A1 (en) 2011-10-05
JP4755649B2 (ja) 2011-08-24
US20100144642A1 (en) 2010-06-10
MX2007003624A (es) 2007-06-13
RU2361877C2 (ru) 2009-07-20
ES2386498T3 (es) 2012-08-22
KR101035283B1 (ko) 2011-05-18
EP1803732A2 (en) 2007-07-04
CN101935345A (zh) 2011-01-05
CN101935345B (zh) 2013-12-11
EP2371847B1 (en) 2013-11-20
WO2006032216A2 (es) 2006-03-30
ES2445707T3 (es) 2014-03-04
KR20100028645A (ko) 2010-03-12
EP1803732B1 (en) 2012-02-22
CN101065398A (zh) 2007-10-31
KR101054332B1 (ko) 2011-08-04
AU2005287757B2 (en) 2010-07-29
AU2010219312B2 (en) 2011-10-06
CA2581110C (en) 2013-04-02
US20090171069A1 (en) 2009-07-02
RU2007115411A (ru) 2008-10-27
BRPI0515893B1 (pt) 2020-09-15
US8324164B2 (en) 2012-12-04
CA2797769A1 (en) 2006-03-30
CU23504A1 (es) 2010-04-13
BRPI0515893B8 (pt) 2021-05-25
WO2006032216A3 (es) 2007-05-18
KR20070073787A (ko) 2007-07-10
AR051928A1 (es) 2007-02-21
BR122018077204B8 (pt) 2021-07-27
BRPI0515893A8 (pt) 2019-01-02
JP2008514553A (ja) 2008-05-08
CA2797769C (en) 2015-09-15
DK2371847T3 (da) 2014-02-03
CA2581110A1 (en) 2006-03-30
US8383771B2 (en) 2013-02-26
ATE546462T1 (de) 2012-03-15
AU2005287757A1 (en) 2006-03-30
CN101065398B (zh) 2012-12-19
AR074924A2 (es) 2011-02-23
ZA200702938B (en) 2008-08-27

Similar Documents

Publication Publication Date Title
BRPI0511421A (pt) composições cosmética e farmacêutica para tratar materiais contendo queratina, uso de composições cosméticas, molécula efetora que liga queratina, uso da mesma, e, processo
CL2018000537A1 (es) Anticuerpo anti-factor d del complemento; polinucleótido codificante; vector que comprende dicho polinucleótido; célula húesped que comprende dicho vector; método de fabricación de anticuerpo; composición farmacéutica que lo comprende; uso del anticuerpo para tratar trastornos inflamatorios o trastornos oculares (divisional de cl 1001-2009).
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
AR079114A1 (es) Proteinas de enlace de antigenos anti-orai1 y usos de las mismas
NO20092121L (no) Humaniserte anti-faktor D-antistoffer og anvendelser derav
CY1119127T1 (el) Επιτοποι σκληροστινης
BR112022016550A2 (pt) Proteínas de ligação a flt3 e métodos de uso
AR064642A1 (es) Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
MX351247B (es) Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
BRPI0912411B8 (pt) uso de uma muteína de interleucina humana-2 (muteína de hil-2) e composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune
NZ602943A (en) Modified binding proteins inhibiting the vegf-a receptor interaction
EA201100072A1 (ru) Новые композиции и способы
DK1904635T3 (da) Glycosyleret IL-7, fremstilling og anvendelser
DK2231860T3 (da) Polypeptid afledt protein A og i stand til at binde PDGF
CL2007002492A1 (es) Compuestos derivados de bi-,tri o policiclos no aromaticos, inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo i; proceso de preparacion de estos; composicion famaceutica que los comprende; uso en el tratamiento de enfermedades tales como la obesidad, diabetes y dislipidemia, entre otras.
BRPI0607326A2 (pt) composição de vacina, variante de peptìdeo de survivina, uso da referida composição, kit em partes e medicamento
BRPI0715746B8 (pt) composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica os compreendendo
BRPI0515893A (pt) peptìdeos da proteìna humana de estresse térmico, composição farmacêutica e método de tratamento da artrite reumatóide
EA201100071A1 (ru) Новые композиции и способы
ATE506957T1 (de) Prophylaktisches/therapeutisches mittel für neurodegenerative erkrankungen
BR112021025720A2 (pt) Conjugados anticorpo-fármaco de fator antitecido e métodos relacionados
EA201070725A1 (ru) Бис-пиридилпиридоны как антагонисты рецептора 1 меланинконцентрирующего гормона
PE20050197A1 (es) Anticuerpos de virus anti-dengue, composiciones, metodos y usos
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
BRPI0407031A (pt) Composições e métodos para tratamento de câncer empregando igsf9 e liv-1

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/09/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF